Milestone Scientific Inc. (MLSS) Financial Ratios
29 years of historical data (1996–2024) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low24.2·High24.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low24.1·High166.0
P/B Ratio
↑
6.42
↓-19% vs avg
5yr avg: 7.97
30Y Low2.8·High120.8
ROE
↑
-68.1%
-1% vs avg
5yr avg: -67.3%
30Y Low-477%·High39%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MLSS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Milestone Scientific Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $37M | $77M | $50M | $34M | $142M | $134M | $64M | $12M | $39M | $38M | $50M |
| Enterprise Value | $34M | $74M | $48M | $26M | $128M | $120M | $62M | $11M | $36M | $34M | $46M |
| P/E Ratio → | -7.94 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.27 | 8.88 | 5.11 | 3.85 | 13.76 | 24.59 | 7.59 | 1.22 | 3.42 | 3.60 | 5.31 |
| P/B Ratio | 6.42 | 13.13 | 6.27 | 3.39 | 8.74 | 8.30 | 39.04 | 7.66 | 5.15 | 4.42 | 5.49 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MLSS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.54 | 4.85 | 2.92 | 12.38 | 22.15 | 7.41 | 1.14 | 3.19 | 3.26 | 4.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MLSS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Milestone Scientific Inc. earns an operating margin of -78.3%. Operating margins have expanded from -100.2% to -78.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -68.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.6% | 74.6% | 69.1% | 55.7% | 61.3% | 66.6% | 68.3% | 46.1% | 61.8% | 60.2% | 67.9% |
| Operating Margin | -78.3% | -78.3% | -72.3% | -100.2% | -71.6% | -137.1% | -47.8% | -83.1% | -46.4% | -62.1% | -32.2% |
| Net Profit Margin | -54.6% | -54.6% | -70.5% | -98.9% | -66.2% | -134.9% | -89.8% | -77.2% | -46.0% | -56.7% | -57.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.1% | -68.1% | -76.9% | -66.4% | -42.2% | -82.7% | -476.7% | -164.6% | -64.7% | -67.2% | -45.2% |
| ROA | -44.5% | -44.5% | -55.3% | -52.0% | -34.6% | -56.2% | -116.1% | -67.5% | -35.6% | -45.1% | -36.1% |
| ROIC | -121.3% | -121.3% | -147.7% | -346.1% | -227.6% | -378.5% | -656.9% | -212.4% | -80.1% | -98.6% | -47.3% |
| ROCE | -94.2% | -94.2% | -76.0% | -65.1% | -44.2% | -81.4% | -253.4% | -153.4% | -60.0% | -73.6% | -25.3% |
MLSS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $349054, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.05 | 0.05 | 0.04 | 0.06 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.32 | -0.82 | -0.87 | -0.82 | -0.92 | -0.49 | -0.35 | -0.42 | -0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -451.01 | -412.21 | — | — | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($349054)
MLSS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Milestone Scientific Inc.'s current ratio of 2.48x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.49x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.93x to 2.48x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | 2.48 | 3.51 | 3.93 | 6.11 | 6.45 | 1.23 | 1.20 | 1.79 | 2.54 | 3.24 |
| Quick Ratio | 1.49 | 1.49 | 2.65 | 3.39 | 5.62 | 5.61 | 0.90 | 0.81 | 1.28 | 1.62 | 2.08 |
| Cash Ratio | 0.87 | 0.87 | 1.94 | 2.64 | 4.77 | 4.94 | 0.31 | 0.15 | 0.39 | 0.72 | 1.15 |
| Asset Turnover | — | 0.88 | 0.86 | 0.64 | 0.52 | 0.28 | 1.28 | 1.50 | 0.72 | 0.77 | 0.74 |
| Inventory Turnover | 0.59 | 0.59 | 1.15 | 2.18 | 2.59 | 0.75 | 1.64 | 2.70 | 1.28 | 0.91 | 0.72 |
| Days Sales Outstanding | — | 20.11 | 11.61 | 28.75 | 33.41 | 72.54 | 74.56 | 78.84 | 105.50 | 122.47 | 71.22 |
MLSS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Milestone Scientific Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $80M | $73M | $71M | $69M | $63M | $46M | $35M | $33M | $27M | $21M |
Peer Comparison
Compare MLSS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MLSSYou | $37M | -7.9 | — | — | 74.6% | -78.3% | -68.1% | -121.3% | — |
 XRAY | $2B | -3.7 | 7.2 | 21.1 | 50.0% | 6.8% | -36.4% | 5.1% | 4.1 |
 HSIC | $8B | 21.6 | 10.9 | 14.1 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 NVST | $4B | 86.7 | 13.3 | 17.5 | 55.0% | 8.3% | 1.6% | 4.8% | 5.0 |
 ALGN | $12B | 29.8 | 13.9 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 SRDX | $615M | -52.4 | 200.6 | — | 73.8% | -4.5% | -9.7% | -3.7% | 10.9 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See MLSS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLSS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLSS vs XRAY
Side-by-side business, growth, and profitability comparison vs DENTSPLY SIRONA Inc..
Start ComparisonMLSS — Frequently Asked Questions
Quick answers to the most common questions about buying MLSS stock.
What is Milestone Scientific Inc.'s P/E ratio?
Milestone Scientific Inc.'s current P/E ratio is -7.9x. The historical average is 21.3x.
What is Milestone Scientific Inc.'s ROE?
Milestone Scientific Inc.'s return on equity (ROE) is -68.1%. The historical average is -90.7%.
Is MLSS stock overvalued?
Based on historical data, Milestone Scientific Inc. is trading at a P/E of -7.9x. Compare with industry peers and growth rates for a complete picture.
What are Milestone Scientific Inc.'s profit margins?
Milestone Scientific Inc. has 74.6% gross margin and -78.3% operating margin.